Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound
This article was originally published in PharmAsia News
Executive Summary
Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.
You may also be interested in...
Eisai Buys U.S. Biotech AkaRx With Chinese And Indian Markets In Sight
Eisai plans to acquire U.S. biotech AkaRx for $225 million in a move that will give the Japanese outfit access to AKR-501, a novel small-molecule thrombopoietin mimetic under development to treat thrombocytopenia resulting from viral hepatitis and other problems
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.